1-[5-(4-ethylphenyl)thiophen-2-yl]ethan-1-one | 93599-28-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[5-(4-ethylphenyl)thiophen-2-yl]ethan-1-one
• 英文别名: 2-Acetyl-5-(p-ethylphenyl)thiophene；1-[5-(4-Ethylphenyl)thiophen-2-yl]ethanone
• CAS: 93599-28-1
• 化学式: C₁₄H₁₄OS
• mdl: MFCD11204657
• 分子量: 230.331
• InChiKey: AKZCUDQSAVKQPF-UHFFFAOYSA-N

物化性质

• 沸点：
  382.4±37.0 °C(Predicted)
• 密度：
  1.104±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.214
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[5-(4-ethylphenyl)thiophen-2-yl]ethan-1-one 在 吡啶 、 盐酸羟胺 作用下， 以 乙醇 为溶剂， 反应 5.0h， 以85%的产率得到1-[5-(4-Ethyl-phenyl)-thiophen-2-yl]-ethanone oxime
  参考文献：
  名称：

  Shridhar, D. R.; Sastry, C. V. Reddy; Chaturvedi, S. C., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1984, vol. 23, # 7, p. 692 - 694

  摘要：

  DOI：
• 作为产物：
  描述：

  4-乙基苯胺 在 盐酸 、 18-冠醚-6 、 sodium nitrite 作用下， 反应 8.0h， 生成 1-[5-(4-ethylphenyl)thiophen-2-yl]ethan-1-one
  参考文献：
  名称：

  Shridhar, D. R.; Sastry, C. V. Reddy; Chaturvedi, S. C., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1984, vol. 23, # 7, p. 692 - 694

  摘要：

  DOI：

文献信息

• Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070173519A1

  公开（公告）日：2007-07-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  由式（1）表示的吡唑吡嘧啶衍生物及其药用盐对MAPKAP-K2表现出优异的抑制活性。因此，含有该化合物作为活性成分的药物预计对治疗由MAPKAP-K2介导的疾病，如炎症性疾病、自身免疫疾病、破坏性骨病、癌症和/或肿瘤生长等方面具有有效性。
• A Zwitterionic Palladium(II) Complex as a Precatalyst for Neat-Water-Mediated Cross-Coupling Reactions of Heteroaryl, Benzyl, and Aryl Acid Chlorides with Organoboron Reagents
  作者：Visannagari Ramakrishna、Morla Jhansi Rani、Nareddula Dastagiri Reddy

  DOI：10.1002/ejoc.201701241

  日期：2017.12.29

  A zwitterionic palladium(II) complex has been found to be an efficient catalyst for Suzuki–Miyaura cross‐coupling reactions of aryl and heteroaryl organoboron reagents with various heteroaryl chlorides, aryl‐ and heteroarylmethyl chlorides, and aryl acid chlorides in neat water.

  两性离子钯（II）络合物是在纯净水中使芳基和杂芳基有机硼试剂与各种杂芳基氯化物，芳基和杂芳基甲基氯化物以及芳基酰氯发生铃木–宫浦交叉偶联反应的有效催化剂。
• [EN] ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING<br/>[FR] ANALOGUES DE LA FÉXARAMINE ET PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：SALK INST FOR BIOLOGICAL STUDI

  公开号：WO2015138969A1

  公开（公告）日：2015-09-17

  Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

  揭示了具有化合物配方实施例的小说化合物，制备方法的实施例，以及包含它们的组合物。还揭示了一种治疗或预防受试者代谢紊乱的方法实施例，包括向受试者（例如，通过胃肠道）施用所述化合物的一种或多种治疗有效量，从而激活肠道中的FXR受体，并治疗或预防受试者的代谢紊乱。此外还揭示了一种治疗或预防受试者肠道区域炎症的方法实施例，包括向受试者（例如，通过胃肠道）施用所述化合物的一种或多种治疗有效量，从而激活肠道中的FXR受体，并治疗或预防受试者肠道区域的炎症。
• Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation
  申请人：Lowe Derek B.

  公开号：US20090047687A1

  公开（公告）日：2009-02-19

  This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.

  本发明涉及一种新型的茚环乙酸衍生物，其在治疗糖尿病、肥胖症、高脂血症和动脉粥样硬化等疾病方面具有用途。本发明还涉及在制备茚环乙酸衍生物时有用的中间体和制备方法。
• Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof
  申请人：UNOKI Gen

  公开号：US20090054472A1

  公开（公告）日：2009-02-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  式（1）所表示的吡唑并嘧啶衍生物及其药学上可接受的盐，表现出对MAPKAP-K2的优异抑制活性。因此，含有该化合物作为活性成分的药物预计将对由MAPKAP-K2介导的疾病具有治疗作用，例如，炎症性疾病、自身免疫性疾病、破坏性骨病、癌症和/或肿瘤生长。